• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.61% Nasdaq Up0.26%

    Valeant Pharmaceuticals International, Inc. (VRX)

    -NYSE
    144.86 Down 1.20(0.82%) 2:33PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Valeant Pharmaceuticals International, Inc.
    2150 St. Elz
    Laval, QC H7L 4A8
    Canada - Map
    Phone: 514-744-6792
    Fax: 514-744-6272
    Website: http://www.valeant.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Delivery
    Full Time Employees:17,200

    Business Summary 

    Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Valeant Pharmaceuticals International, Inc.

    Corporate Governance 
    Valeant Pharmaceuticals International, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 1.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. J. Michael Pearson , 55
    Chairman and Chief Exec. Officer
    7.00M0.00
    Mr. Howard Bradley Schiller , 52
    Chief Financial Officer, Principal Accounting Officer, Exec. VP and Director
    2.80M0.00
    Mr. Robert Roswell Chai-Onn , 44
    Chief Legal Officer, Head of Corp. & Bus. Devel., Exec. VP, Gen. Counsel and Corp. Sec.
    2.10M0.00
    Mr. Laizer D. Kornwasser , 43
    Exec. VP and Company Group Chairman
    1.24M0.00
    Mr. Christopher Bovaird , 54
    VP of Corp. Fin.
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders